Cullinan Therapeutics: Deep Cash Cushion, Cheap Optionality on Multiple Clinical Readouts
Cullinan Therapeutics (CGEM) is a clinical-stage oncology and immuno-immunology developer trading at roughly $700M market cap while sitting on a substantial cash reserve. With CLN-978 advancing toward clinical readouts, a positive zipalertinib trajectory and a reported cash runway into 2028, Cullinan offers an asymmetric long opportunity: the marke…